An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
about
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimenFactors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS.Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challengeComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVMucosal immunization of cynomolgus macaques with two serotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: stimulation of humoral, mucosal, and cellular immunityImmunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectorsConstruction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit.Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.Immune responses in macaques to a prototype recombinant adenovirus live oral human papillomavirus 16 vaccine.Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication.Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particlesRapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in miceA replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys.Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines.Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges.Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rheLow-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaReplicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac2A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola InfectionReplicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route.Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection.Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge.Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines.Prospects for oral replicating adenovirus-vectored vaccines.Novel viral vectors in infectious diseases.Induction of PrPSc-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development
P2860
Q33639684-AD2B752A-7C3B-4739-819B-741D6077CF02Q33649657-3D83DF90-C6FF-4F0D-B70A-169FF3991CEEQ33785371-7CD16FFD-BEEC-4EE5-A575-A4D719CB7D4EQ33786386-0BBEAC2E-306F-4733-9B43-90F6020644D9Q33799497-94FDD922-E86B-4712-BE21-14D6A2811D3AQ33800033-1EBFA5E2-3BCF-46A1-A6FC-D943F04D9CB4Q33823503-9B57A67C-D038-4682-B6CE-050F87098BD0Q33835295-B7CEFB20-A3F2-4A6D-9991-D9F8A51F2270Q33852720-F669208A-01DA-4424-96EE-980AC3CCDE72Q33872445-4192BF76-4C12-4271-B7C1-382E2710279EQ33932258-395C1258-20C7-4179-A6FB-ECA25B4C9A68Q33966586-43382E70-26C1-44F1-A917-59E0DA6225CEQ34228507-00C6AA55-CB6D-4963-A5D7-A68781001F11Q34260720-D652B5F8-961C-46EF-8309-30A3C3ABF0E8Q34339609-290CAD62-A3B0-4082-97CE-9BE2CF0202AFQ34465510-77737AD9-77B2-4EA1-AF29-1C5507C33A5AQ34574409-833E1877-8878-4A09-A44F-2ED3B5A76FC8Q34651604-E7D3BA8C-887F-47E7-863C-588756DF24EDQ34700810-9F915349-522B-46A5-9F45-48CD4C97C899Q34889790-A4A56E76-7D5F-4B28-915C-14971CDC8F93Q34992681-B2B09989-E98E-48B1-B147-505365C9D370Q35155380-189F5658-E28A-4BC4-B546-2D5638E7B558Q35160124-1ED4AF76-78C1-4CC5-BAEC-C41427300BF7Q35182076-4F8B0D32-8ABA-475F-96C2-7F124FBD6EFAQ35785031-5794B491-1B01-4246-BB63-48F6248BBBBEQ35826525-A4DEFB2B-580D-42DB-BE73-FDE651768690Q35867976-4A7D358C-15FA-48C1-A951-097AE43C9FA0Q35917501-B7586693-5168-4E9C-99EA-F2643040F7A6Q35940685-C64C5C6F-9D11-415C-B026-349C362B38E4Q36373305-C50D6BA7-780F-4441-A844-085AB2C4874CQ36954239-1C5D82A3-2C74-46B3-9731-A681D79F0955Q36961218-D1FEACDE-F3AC-4656-A8A0-106BB983596FQ37033311-870C49B1-97B8-4613-81EA-91909382D836Q37297052-9370521F-D90B-43BE-824F-64259867594EQ37347813-F5C15F8B-CA58-40B1-AE4E-4807FDF2EE13Q38109356-3498B31F-08FF-467D-95AD-C257C4CDD6BDQ40059020-87485DDD-FDB1-4A6E-84E3-25A0825824D8Q41992326-6390D532-21B8-4D0D-93F4-4A2B4EEE7198Q56993265-78A380C0-10EA-4985-A1DB-EA27852AC878
P2860
An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
An adenovirus-simian immunodef ...... en following vaginal challenge
@ast
An adenovirus-simian immunodef ...... en following vaginal challenge
@en
type
label
An adenovirus-simian immunodef ...... en following vaginal challenge
@ast
An adenovirus-simian immunodef ...... en following vaginal challenge
@en
prefLabel
An adenovirus-simian immunodef ...... en following vaginal challenge
@ast
An adenovirus-simian immunodef ...... en following vaginal challenge
@en
P2093
P2860
P921
P1433
P1476
An adenovirus-simian immunodef ...... en following vaginal challenge
@en
P2093
Alipanah S
Eldridge J
Richardson E
Robert-Guroff M
P2860
P304
P407
P577
1997-11-01T00:00:00Z